Trial Profile
Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature (GM) After Total Hip Arthroplasty (THA)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Emiplacel (Primary)
- Indications Muscle injury
- Focus Therapeutic Use
- Sponsors Pluri; Pluristem Therapeutics
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 10 Oct 2018 According to a Pluristem Therapeutics media release, Dr. Tobias Winkler, at the Berlin-Brandenburg Center for Regenerative Therapies is principal investigator of this study.
- 10 Oct 2018 According to a Pluristem Therapeutics media release, results were published in the peer-reviewed Journal of Cachexia, Sarcopenia and Muscle.